PharmaEssentia

PharmaEssentia is a global biopharmaceutical innovator focused on the research, development, and commercialization of new biologics for challenging diseases, particularly in hematology, oncology, and immunology. Founded in 2003, the company leverages its proprietary technology platforms to transform the risk/benefit profiles of existing therapies and provide best-in-class treatment options for patients with rare blood cancers. Headquartered in Taipei, Taiwan, with a significant U.S. commercial arm based in Burlington, Massachusetts, PharmaEssentia has expanded its global presence across Asia, the U.S., and other international markets. The company is known for its flagship product, BESREMi® (ropeginterferon alfa-2b-njft), and maintains a diversifying pipeline of clinical-stage candidates targeting various malignancies and immune system disorders.